Fibrotech to progress fibrosis drug after new funding
This article was originally published in Scrip
Executive Summary
The Australian venture Fibrotech Therapeutics has received A$3 million ($2 million) in new funding which it says will enable its lead candidate to complete Phase I trials. The University of Melbourne spin-out is developing analogues of the mast cell stabiliser tranilast for use in chronic fibrotic disorders related to kidney disease, heart failure, pulmonary fibrosis and arthritis.